Vascular restenosis, an overreaction of biological response to injury, is initialized by thrombosis and inflammation. This response is characterized by increased smooth muscle cell migration and proliferation. Available pharmacological treatments include anticoagulants, antiplatelet agents, immunosuppressants, and antiproliferation agents. Protein kinase C (PKC), a large family of serine/threonine kinases, has been shown to participate in various pathological stages of restenosis. Consequently, PKC inhibitors are expected to exert a wide range of pharmacological activities therapeutically beneficial for restenosis. In this review, the roles of PKC isozymes in platelets, leukocytes, endothelial cells, and smooth muscle cells are discussed, with emphasis given to smooth muscle cells. We will describe cellular and animal studies assessing prevention of restenosis with PKC inhibitors, particularly targeting -a, -b, -d, and -z isozymes. The delivery strategy, efficacy, and safety of such PKC regulators will also be discussed.
Introduction
Vascular restenosis is the renarrowing of a blood vessel after surgical and mechanical intervention in patients with occlusive vascular diseases. Vessel renarrowing can be caused by constrictive wall recoiling and intimal hyperplasia. 1, 2 Recoil may be minimized by stent placement, but intimal hyperplasia still leads to instent restenosis at an inherent rate of approximately 25%. Although restenosis is a multiplestaged proliferative disease, it is now known that vascular smooth muscle cell (VSMC) migration and proliferation play a critical role in its formation. [3] [4] [5] Protein kinase C (PKC), a large family of serine/threonine kinases, plays multiple essential (patho)physiological roles in the cardiovascular system by governing various signaling cascades. 6, 7 Emerging evidence has shown that PKC is involved in the formation of intimal hyperplasia. In this review, we will first introduce the basic knowledge of PKC biology and then elaborate on the roles of PKC isozymes and effects of PKC inhibitors in the progression of restenosis, particularly in SMC migration and proliferation, and finally discuss the delivery strategy, efficacy, and safety of PKC regulators.
Protein Kinase C Biology
The PKC family includes 10 homologous protein kinases consisting of a regulatory domain and a catalytic domain. The catalytic region is highly conserved and binds adenosine triphosphate (ATP) and protein substrates; the regulatory region contains motifs that bind the second messengers diacylglycerol (DAG) and calcium in the presence of phosphatidylserine and is less conserved. Depending on the regulatory region, PKCs can be categorized into 3 groups: the conventional PKCs (Àa, ÀbI, ÀbII, and Àg) have DAG-and Ca 2þbinding domains; the novel PKCs (Àd, Àe, ÀZ, Ày) have DAG-but not Ca 2þ -binding domains; the atypical PKCs (Àl/i, and Àz) have neither Ca 2þ -nor DAG-binding domains. The distribution and abundance of each isozyme varies by cell subtype. For example, the levels of PKC-a, Àb, Àd, and Àe, but not PKC-z, are relatively high in human smooth muscle cells. 8 In endothelial cells, the level of PKC-d is lower than PKC-z. 9, 10 Generally, PKC is activated by G-protein coupled receptors and translocates from the cytosol to the plasma/ nuclear membrane or cytoskeleton. Mitogen-activated protein kinases, such as ERK, p38, and JNK, are common downstream effectors of PKC. [11] [12] [13] Akt signaling is also modulated by PKC. 14 Cell migration-related molecules, such as focal adhesion kinase, [15] [16] [17] paxillin, [17] [18] [19] and vinculin, 19 also can be activated by PKC. It is likely that different PKCs preferentially activate different substrates/effectors, yet relatively few isozyme-specific substrates have been identified.
Protein Kinase C and Restenosis
Therapeutic intervention of vascular diseases usually initiates endothelial denudation, artery stretching, and plaque compression, triggering a substantial local thrombotic and inflammatory reaction. Platelets, clotting proteins, and inflammatory cells adhere to the exposed subendothelium forming a thin carpet of thrombus. Chemocytokines released from platelets and inflammatory cells recruit more circulating leukocytes to the injury site. Inflammatory cells infiltrate the blood vessel, releasing cytokines, such as tumor necrosis factor a (TNF-a), monocyte chemotactic protein-1 (MCP-1), and growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and basic fibroblast growth factor (bFGF). These bioactive molecules stimulate medial SMCs to migrate to and proliferate in neointima, leading to intimal hyperplasia. In this section, we will discuss the roles of PKC in multiple stages of restenosis, with an emphasis on SMC migration and proliferation, which are currently regarded as key determinants in the etiology of restenosis.
Role of PKC in Restenosis Initiation
Protein kinase C and platelet activation. Both experimental 20 and clinical 21 studies showed acute accumulation of platelets surrounding the stent struts. Platelet-derived growth factor is an important stimulus for VSMC migration and proliferation. Four major platelet-expressed isozymes, PKC-a, Àb, Àd, and Ày, play distinct roles in its aggregation and secretion. It seems that conventional PKCs promote and novel PKCs inhibit platelet secretion and thrombus formation. 22, 23 Blocking PKC-a by gene deletion, immunodepletion, or drug inhibitor (Go6850 and Go6976) abrogated platelet secretion in both mice 24 and humans. [25] [26] [27] Protein kinase C d and Ày were also shown to modulate platelet secretion but in a more complicated manner. One set of studies suggested that PKC-d 28, 29 and Ày 30 play negative roles in platelet activation. Pharmacological inhibition by rottlerin potentiated human platelet aggregation, which was initiated by alboaggregin A 28 or collagen. 29 Knocking out either PKC-d 29 or Ày 30 potentiated murine platelet aggregation. However, another set of studies implied that PKC-d 31 and Ày 32,33 are required for platelet activation: Gene deficiency or selective inhibition (by dV1-2) of PKC-d impaired proteaseactivated receptor 4-mediated platelet secretion in the absence and presence of thromboxane A2. 31 Deficiency of PKC-y impaired murine platelet activation triggered by glycoprotein VI 31 or thrombin. 32 Inhibition of PKC-y by selective antagonistic receptor for activated C kinase (RACK) peptide exerted a similar result. 32 Protein kinase C and inflammation. Besides platelets, leukocytes are another primary source of cytokines and growth factors for stimulating VSMC migration and proliferation. Leukocyte recruitment is facilitated by endothelial cellexpressed adhesion molecules. Activation of PKC-a, 34 Àb, 35 and Àz, 36 as measured by protein phosphorylation, 34 translocation, 35, 36 or enzyme activity, 36 were found to potentiate adhesion molecule expression. Monocyte chemotactic protein-1 is another molecule that enlists leukocytes to endothelial layer. Transfection of endothelia with PKC-e antisense oligonucteotide abolished shear stress-induced MCP-1 expression, suggesting that PKC-e may regulate MCP-1 expression in the endothelial cells. 37 Instead of regulating endothelial cell function, PKC-z directly participates in leukocyte infiltration. Selective blockade of this isozyme by peptide inhibitor impaired interleukin 8-induced neutrophil migration. 38 
Role of PKC in SMC Migration
Smooth muscle cell migration and proliferation are crucial events in the pathogenesis of intimal hyperplasia. Under normal conditions, vascular medial SMCs are quiescent and exhibit low levels of migrating or proliferating activity. With the stimuli of cytokines/growth factors released in the injury area, medial SMCs migrate to the injury areas and proliferate at the site in an attempt to repair the wound. Smooth muscle cell migration involves intracellular actin polymerization, adhesion molecule expression at the cell surface, and extracellular activation of matrix metalloproteinase. With microchemotaxis chamber or morphological analysis, PKC-a, 39 Àb, 40 and Àd 12,19,41-43 were reported to modulate SMC migration by either promoting actin polymerization or enhancing cell adhesion. It has been found that matrix metalloproteinases mediate adipokine resistin-induced VSMC migration. 44 
Role of PKC in SMC Proliferation
Several lines of evidence have established that certain PKCs regulate VSMC proliferation. Known PKCs include Àa, Àb, Àd, and Àz isozymes.
Protein kinase C-a is one of the most prevalent isozymes in vascular SMCs. 8, 39, 45 Marilley et al 46 observed that there is a positive correlation between cell proliferation and PKC-a levels in human aortic vascular SMCs. Selective depletion of PKC-a with PKC-a antisense oligodeoxynucleotide caused 45% to 55% inhibition of 3 H-thymidine incorporation into SMCs. 45 However, Sasaguri et al 47 and Wang et al 48 showed different results. Using cell cycle analysis or cell counting method, they found that, instead of promoting cell growth, PKC-a mediated SMC growth inhibition in porcine and rat VSMCs.
Protein kinase C b appears preferentially activated by high glucose [49] [50] [51] and low-density lipoprotein 52 in human and rat aortic SMCs. Based on studies with [ 3 H]thymidine incorporation assay, PKC-b was also found to mediate synergistic proliferative effect of PDGF and high glucose level on human coronary SMCs. 53 Selective PKC-b inhibitor LY-379196 attenuated DNA synthesis and cell growth. Further animal study showed that PKCb null mice or mice treated with the PKC-b inhibitor LY379196 experienced significantly decreased neointimal expansion. 54 Protein kinase C d mediates vascular SMC proliferation, triggered by PDGF, bFGF, and IGF-I. Using [ 3 H]thymidine incorporation assay, Yamaguchi et al 12 reported that PDGFinduced SMC proliferation is mediated by PKC-d. 12 Going one step further, Ginnan et al 13 showed that ERK1/2 is an effector molecule of PKC-d after PDGF stimulus. Studies using [ 3 H]thymidine incorporation, 5-bromo-2-deoxyuridine labeling, and cell counting assays demonstrated that this kinase also mediated bFGF and IGF-I-stimulating VSMC growth. 11, 14, 55 In contrast, Liu and his colleagues demonstrated the opposite results: overexpression of PKC-d inhibited PDGF-induced cell growth in rat vascular SMCs. 43 It should be noted that, PKC-d also plays a role in regulating apoptotic progress and hence interferes with cell homestasis. An exacerbated vein graft arteriosclerosis has been observed in PKC-d-null mice. 56 Three research groups demonstrated that PKC-z is involved in SMC growth and intimal hyperplasia. However, the exact function of PKC-z varies in these studies. Using with selective PKC-z antisense oligodeoxyribonucleotide and found that neointimal formation was reduced significantly. These 2 studies suggested that PKC-z plays a favorable role for cell growth at least in rats. However, in rabbit aortic SMCs, activation of PKC-z by bFGF and interleukin is correlated with inhibition of cell proliferation, while inhibition of this kinase with antisense oligonucleotide stimulates cell proliferation. 59 In summary, a, b, d, and z PKCs have been found to be involved in modulating VSMC proliferation. Among these isozymes, PKC-b seems to play a consistent role in promoting cell growth, while many conflicting results exist with other 3 PKCs. The conflicting results may reflect differences in between species, the use of different mitogens, and the use of different and sometime isozyme-non-selective tools in the studies.
Overall, vascular restenosis is a multistaged disease in which smooth muscle cell migration and proliferation play a central role (Figure 1 ). Different PKC isozymes seem preferentially involved in various stages of disease progression as summarized in Figure 1 .
Protein Kinase C Inhibitor and Restenosis Prevention
Restenosis is a multistaged vascular disease. Drugs with antithrombotic, anti-inflammatory, and antiproliferative activities could be effective in preventing this disease at different stages. Early attempts focused on antithrombotic agents, but clinical reports demonstrate a limited success. 60 Smooth muscle cell migration and proliferation are currently considered to play a key role. Emerging data have demonstrated that PKC inhibitors are effective in inhibiting SMC activation. Table 1 lists some common PKC inhibitors. These inhibitors belong to different structure classes and take effect through different mechanisms.
Protein Kinase C Inhibitors
Staurosporine, calphostin C, and chelerythrine are known pan-PKC inhibitors. They are effective inhibitors of both conventional and novel PKC isozymes. Yang et al found that staurosporine inhibited oxidized low-density lipoprotein (LDL)induced rat VSMC growth; 62 calphostin C and chelerythrine abolished lipoprotein lipase-induced human VSMC proliferation; 63 chelerythrine also decreased phenylephrine-induced SMC proliferation. 64 In contrast to above pan-PKC inhibitors, some PKC regulators show a greater isozyme selectivity.
Protein kinase C a inhibitor. Available PKC-a inhibitors include antisense oligonucteotides ISIS9606 and ISI3521. The ATP-binding site inhibitor, Go6976, also selectively inhibits PKC-a at lower concentrations (0.1-2 nmol/L). However, ATP-binding site inhibitors are less selective. They can inhibit a number of other protein kinases at higher concentrations. 61 Although direct experiments examining the role of PKC-a inhibitors in restenosis are limited, based on the promoting role of PKC-a in SMC proliferation, 45, 46 it is worthwhile to test the potential suppressive effect of PKC-a inhibitor on VSMC growth. In addition to SMCs, this inhibitor might abrogate platelet activation 27 and reverse endothelial dysfunction, 34, 65 which also are therapeutically beneficial to treat restenosis.
Protein kinase C b inhibitor. Available ATP-binding site inhibitors of PKC-b include LY317615, LY333531, LY379196, and CGP53353. They may have the same limitation as discussed for the PKC-a inhibitors. 61 Competitive inhibitors of localization of activated PKC, bIV5-3, and bIIV5-3 have also been used, and they show a selective effect on the corresponding isozymes bI and bII PKC. 66 Compared to PKC-a inhibitor, more experimental evidence has been obtained with PKC-b inhibitors in the vascular system. In vitro studies showed that PKC-b inhibition attenuated SMC proliferation. Consistent results were obtained on cells isolated from rats, 50,51,67 rabbits, [68] [69] [70] pigs, 71 and humans. 49, 53, 72 The suppressive effect on cell migration after PKC-b deactivation was also reported. 40 Further in vivo data confirmed that mice fed with LY333531 displayed significantly decreased neointimal thickening in response to acute femoral artery injury. 54 a Because the ATP-binding site in protein kinases is so similar, generating ATP-binding site inhibitors that are specific for one protein kinase was found to be a challenge. Many of these inhibitors, that were initially thought to be highly specific, were subsequently found to affect multiple kinases from a variety of protein kinase families. 61 Protein kinase C d inhibitor. Available inhibitors include the peptide inhibitors of anchoring of the active enzymes dV1-1 73 , KAI-9803 74 and a less selective, ATP-binding site competitive inhibitor, rottlerin. 75 The efficacy of PKC-d inhibition against VSMC migration has been observed in mechanical stress-and drug-associated cellular models. 19, 41 Also, the effect of inhibition of PKC-d on DNA synthesis and cell proliferation in human VSMCs has been reported. Genetic and pharmacological (by rottlerin) approaches brought about similar results. 55 Different from inhibiting VSMCs, suppressing PKC-d was found to stimulate endothelial growth and angiogenesis, [76] [77] [78] which has not been observed with other PKC isozymes. This is interesting because a differential effect between SMCs and endothelial cells is ideal for an antirestenosis drug. As for animal tests, 2 in vivo studies showed protection by PKC-d peptide inhibitor dV1-1 (combined with PKC-e selective activator pseudo-eRACK) against coronary stenosis both in mice 79 and rats. 80 In murine cardiac allograts, graft coronary artery narrowing related to ischemia-reperfusion injury was suppressed by a brief treatment with pseudo-eRACK and dV1-1. The percentage of luminal narrowing and intima-media ratio were decreased by >60% at 30 days after heart transplantation. 79 In another graft coronary artery disease in rats, one early combination injection of pseudo-eRACK and dV1-1 decreased the percentage of luminal narrowing by 78% and decreased the intima-media ratio by 58% at 90 days after cardiac injury. 80 One potential concern for PKC-d inhibitors is that they might interfere with cellular apoptosis and even aggravate stenosis. An exacerbated vein graft arteriosclerosis has been observed in PKC-d-null mice. 56 Another potential concern is that PKC-d inhibitor, such as rottlerin, may stimulate platelet activation and accentuate thrombosis. 22, 23 However, an in vivo study demonstrated that a deficiency of PKC-d does not stimulate thrombosis in mice. 27 Recent clinical trials showed that the selective peptide PKC-d inhibitor inhibits some of the damage induced by myocardial infarction in patients without inducing any adverse effects. 74 Protein kinase C z inhibitor. Spheciosterol sulfate C is a small molecule that can selectively inhibit PKC-z. 81 However, due to the unclear role of PKC-z in VSMC growth, the efficacy of PKC-z inhibitor in restenosis is uncertain at present.
Because PKC isozymes have unique and sometimes opposing roles, 22,23 the use of isozyme-selective tools is essential. The investigation of PKC inhibitors in vascular restenosis is just at its infancy. Current data of targeting PKC-b and -d are encouraging despite some discrepancy that may be attributed to the tools used and/or some species differences. Inhibitors for PKC-a and -z warrant more studies. Ideally, an antirestenosis drug would be a potent and direct inhibitor of SMC activity with little or no effect on endothelial cells and would not exacerbate platelet aggregation or inflammation. Future studies of screening PKC inhibitors for restenosis ought to be conducted along this direction.
Drug Delivery: Systematically Versus Locally
Systemic administration of antiplatelet agents and anticoagulants show limited success in preventing restenosis in the clinic. 82, 83 Similarly, limited results of success were obtained with oral administration of anti-inflammation, 84, 85 immunosuppression, 86 and antimigration/proliferatition agents. 87 The lack of efficacy in clinical studies may be partly due to either an insufficient drug concentration at the injury site or a lack of chronically adequate dose. In addition, because PKC modulates many critical physiological functions, unwanted drug effects may occur when nonselective PKC inhibitors are systemically administered (it should be noted that sustained delivery of several peptide inhibitors of PKC for a couple of months were found to be safe in animals). 79, 88 Nevertheless, local delivery of PKC inhibitors may be a better approach for preventing restenosis; coated onto stents or balloons, selective PKC inhibitors may be released directly into the injured area with a higher concentration. In fact, current drug-eluting stents/balloons provide a relatively high drug concentration at the site of injury and minimize systemic side effects. 89, 90 Both PKC-bII inhibitor (eg, bIIV5-3) and PKC-d inhibitor (eg, dV1-1) are promising candidates for coating stents or balloons as inhibitors for these 2 PKC isozymes exert satisfactory efficacy and safety in vitro and in animal trials.
Conclusion
Protein kinase C is involved in the transduction of many signals that participate in restenosis, including platelet activation, inflammation, smooth muscle cell migration/proliferation, and endothelial growth. Therefore, inhibition of PKC activity by selective inhibitors is expected to be an effective means for restenotic prevention. Based on current data, PKC-b and PKC-d inhibitors showed some therapeutic promise both in vitro and in vivo. Benefit for other selective PKC inhibitors, such as those targeting -a, -e, and -z subtypes, await further study.
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